Biomarkers of Metastatic Melanoma

Neagu, Monica; Constantin, Carolina; Manda, Gina; Mărgăritescu, Irina

doi:10.2217/17520363.3.1.71

Cited by 26 publications

(13 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melanoma is one of the most aggressive forms of human cancer [1], although it represents only 4% of all skin cancers, it accounts for 80% of skin cancer deaths, and it is placed second after adult leukemia in terms of potential productive life-years loss [2]. The updated figures show that in 2012 only in the United States there are 76,250 new cases accompanied by 9,180 deaths due this cancer [3].…”

Section: Introductionmentioning

confidence: 99%

Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations

Neagu

Constantin²,

Zurac³

2013

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Cutaneous melanoma is an immune-dependent aggressive tumour. Up to our knowledge, there are no reports regarding immune parameters monitoring in longitudinal followup of melanoma patients. We report a followup for 36 months of the immune parameters of patients diagnosed in stages I–IV. The circulatory immune parameters comprised presurgery and postsurgery immune circulating peripheral cells and circulating intercommunicating cytokines. Based on our analysis, the prototype of the intratumor inflammatory infiltrate in a melanoma with good prognosis is composed of numerous T cells CD3+, few or even absent B cells CD20+, few or absent plasma cells CD138+, and present Langerhans cells CD1a+ or langerin+. Regarding circulatory immune cells, a marker that correlates with stage is CD4+/CD8+ ratio, and its decrease clearly indicates a worse prognosis of the disease. Moreover, even in advanced stages, patients that have an increased overall survival rate prove the increase of this ratio. The decrease in the circulating B lymphocytes with stage is balanced by an increase in circulating NK cells, a phenomenon observed in stage III. Out of all the tested cytokines in the followup, IL-6 level correlated with the patient's survival, while in our study, IL-8, IL-10, and IL-12 did not correlate statistically in a significant way with overall survival, or relapse-free survival.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations

Neagu

Constantin²,

Zurac³

2013

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…When following therapy efficacy in melanoma, in addition to the classical circulating markers as LDH, S100 calcium-binding protein B (S100B), melanoma inhibitory activity (MIA) (Neagu et al, 2009), and, lately, ctDNA (Seremet et al, 2019), circulating miRNAs gained interest. As circulating miRNAs have structural stability, they can become robust non-invasive biomarkers when several technicalities can be standardized, such as the sample type (plasma versus serum) and pre-analytical and analytical workflows (Mumford et al, 2018).…”

Section: Mirnas As Therapy Efficacy Markersmentioning

confidence: 99%

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Neagu

Constantin

Creţoiu

et al. 2020

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Skin cancer is, at present, the most common type of malignancy in the Caucasian population. Its incidence has increased rapidly in the last decade for both melanoma and non-melanoma skin cancer. Differential expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers, including skin cancers. Since miRNAs' discovery as regulators of gene expression, their importance grew in the field of oncology. miRNAs can post-transcriptionally regulate gene expression, tumor initiation, development progression, and aggressiveness. Nowadays, these short regulatory RNAs are perceived as one of the epigenetic markers for the identification of new diagnostic and/or prognostic molecular markers. Moreover, as miRNAs can drive tumorigenesis, they might eventually represent new therapy targets. Some miRNAs are pleiotropic, such as miR-214, which was found deregulated in several other tumors besides skin cancers. Some others are specific for one or more skin cancer types, like miR-21 and miR-221 for cutaneous melanoma and cutaneous squamous carcinoma or miR-155 for melanoma and cutaneous lymphoma. The goal of this review was to summarize some of the main miRNA detection technologies that are used to evaluate miRNAs in tissues and body fluids. Furthermore, their quantification limits, conformity, and robustness are discussed. Aberrant miRNA expression is analyzed for cutaneous melanoma, cutaneous squamous cell carcinoma (CSCC), skin lymphomas, cutaneous lymphoma, and Merkel cell carcinoma (MCC). In this type of disease, miRNAs are described as potential biomarkers to diagnose early lesion and/or early metastatic disease. In the future, whether in tissue or circulating in body fluids, miRNAs will gain their place in skin cancer diagnosis, prognosis, and future therapeutic targets.

show abstract

“…Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit [88, 89]. …”

Section: Immunomics Of Skin Cancermentioning

confidence: 99%

“…Due to the complexity of interactions between skin tumors and the immune system, suppressing antitumor responses and the discovery of predictive biomarkers has been particularly challenging [89]. The specific role of immune cell populations in melanoma and in non-melanoma skin cancers continues to be explored in search of new biomarkers and new immune networks .…”

Section: Immunomics Of Skin Cancermentioning

confidence: 99%

Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring

Bulman¹,

Neagu²,

Constantin

2013

Self Cite

View full text Add to dashboard Cite

This review will focus on the elements of the skin’s immune system, immune cells and/or non-immune cells that support immune mechanisms, molecules with immune origin and/or immune functions that are involved in skin carcinogenesis. All these immune elements are compulsory in the development of skin tumors and/or sustainability of the neoplastic process. In this light, recent data gathered in this review will acknowledge all immune elements that contribute to skin tumorigenesis; moreover, they can serve as immune biomarkers. These immune markers can contribute to the diagnostic improvement, prognosis forecast, therapy monitoring, and even personalized therapeutical approach in skin cancer. Immune processes that sustain tumorigenesis in non-melanoma and melanoma skin cancers are described in the framework of recent data.

show abstract

Biomarkers of Metastatic Melanoma

Cited by 26 publications

References 139 publications

Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations

Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring

Contact Info

Product

Resources

About